Enterprise Value
188.3M
Cash
107.2M
Avg Qtr Burn
N/A
Short % of Float
11.92%
Insider Ownership
15.58%
Institutional Own.
68.21%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NERLYNX Details Breast cancer, Sexual desire disorder, Sexual dysfunction | Approved Quarterly sales | |
NERLYNX Details Breast cancer, Cancer, ER+/HER2- breast cancer, Solid tumor/s | Approved Quarterly sales | |
Alisertib Details Cancer, Small cell lung cancer | Phase 2 Data readout | |
Neratinib Details Cervical cancer, Infectious disease, Catheter related blood stream infections | Phase 2 Data readout | |
Neratinib (HKI-272) + fulvestrant + trastzuzumab Details Metastatic breast cancer, Breast cancer, Metastatic breast cancer to brain | Phase 2 Update | |
Trastuzumab Emtansine (T-DM1) With Neratinib Details Breast cancer | Phase 2 Update | |
Neratinib Details Bile duct disease, Cancer | Phase 2 Update | |
Neratinib Details Lung cancer, Non-small cell lung carcinoma | Phase 2 Update | |
Alisertib (2 combo trials) Details Breast cancer, ER+/HER2- breast cancer | Phase 2 Initiation | |
Alisertib+pembrolizumab Details Head and neck squamous cell carcinoma, Cancer | Phase 1/2 Update | |
Alisertib Details Cancer, Non-small cell lung carcinoma | Phase 1/2 Update |